Fulvestrant is used in postmenopausal women with hormone-related breast cancer that is advanced or has spread to other parts of the body (metastatic).
Fulvestrant is used alone or in combination with another medicine called ribociclib (Kisqali) to treat HR-positive, HER2-negative breast cancer in:
women with no prior treatment; or
women whose cancer has progressed after treatment with anti-estrogen medication.
Fulvestrant is used in combination with palbociclib (Ibrance) or abemaciclib (Verzenio) when the cancer has progressed after treatment with anti-estrogen medication.
Fulvestrant may also be used for purposes not listed in this medication guide.
